Effect of the Presence of Brain-Derived Neurotrophic Factor Val66Met Polymorphism on the Recovery in Patients With Acute Subcortical Stroke by 백남종 et al.
Effect of the Presence of Brain-Derived 
Neurotrophic Factor Val66Met Polymorphism 
on the Recovery in Patients With  
Acute Subcortical Stroke
Won-Seok Kim, MD1, Jong Youb Lim, MD1, Joon Ho Shin, MD1, Hye Kyung Park, MD1, 
Samuel Arnado Tan, MD1, Kyoung Un Park, MD2, Nam-Jong Paik, MD1
Departments of 1Rehabilitation Medicine and 2Laboratory Medicine, Seoul National University Bundang Hospital, 
Seoul National University College of Medicine, Seongnam, Korea
Objective  To investigate the effect of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism on the 
recovery after subcortical stroke, using the modified Rankin Scale (mRS).
Methods  Subcortical stroke patients with copies of BDNF Val66Met polymorphism (n=7) were compared to their controls 
(n=7) without a copy of BDNF Val66Met polymorphism after matching for initial severity, location and type of stroke. The 
mRS scores at 1 and 3 months after discharge from the neurorehabilitation unit were compared between the groups.
Results  A repeated measures ANOVA for mRS revealed significant interaction between time and group (F(2, 24) 
=37.2, p<0.001) and a significant effect of time (F(2, 24)=10.8, p<0.001), thereby reflecting significant differences 
between the Met allele (+) group and the Met allele (-) group. There was a significant difference in mRS scores 
at 3 months post-discharge between the two groups (p=0.01) although no difference was evident in mRS scores 
at 1 month post-discharge between the two groups. There were significant improvements between mRS scores 
on admission and mRS scores at 1 month post-discharge (p=0.02), and between mRS scores at 1 month post-
discharge and mRS scores at 3 months post-discharge (p=0.004) in the Met allele (-) group.
Conclusion  BDNF Val66Met polymorphism may be associated with worse functional outcome in Korean patients 
with subcortical stroke. Therefore, BDNF Val66Met polymorphism should be considered as an important 
prognostic factor for recovery and responses to rehabilitation therapies after stroke in Korean patients. There is 
a need for developing different rehabilitation strategies for the population with BDNF Val66Met polymorphism. 
Further studies assessing different outcomes for various functional domains of stroke recovery are needed to 
clarify the role of BDNF Val66Met polymorphism.
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INTRODUCTION
Stroke is a major cause of disability worldwide and 
imposes a great socioeconomic burden [1]. Although it 
is important to maximize the recovery after stroke for 
reducing the stroke-related burden, the recovery and 
response to restorative therapies are highly variable 
between patients [2]. It has been suggested that identi-
fication of the mechanism underlying the variability in 
recovery after stroke is required to provide more effective 
and individualized rehabilitation strategies. Recent ad-
vances in the understanding of the molecular and genetic 
mechanisms of recovery after stroke have indicated the 
possible influence of a specific genetic polymorphism in 
the variability of spontaneous recovery and responses to 
post-stroke therapy [2-4]. 
Brain-derived neurotrophic factor (BDNF) Val66Met 
polymorphism is one of the most investigated genetic 
polymorphisms that are known to be associated with the 
recovery after stroke [2]. BDNF is the most abundant neu-
rotrophic factor in the central nervous system and affects 
neural plasticity [2]. BDNF Val66Met polymorphism is as-
sociated with the reduction in activity-dependent BDNF 
secretion and brain plasticity [5,6], and might lower the 
capacity of functional recovery after stroke. The report 
that 30%−50% of humans have at least one Met allele in 
the BDNF gene indicates the importance of this polymor-
phism [7]. 
Several human observational studies have reported 
that the BDNF Val66Met polymorphism is associated with 
worse functional recovery after stroke [8-10]. Cramer and 
Procaccio reported a possible relationship between the 
presence of the BDNF Val66Met polymorphism and poor-
er recovery from onset of acute stroke to 1 month post-
stroke [8]. The BDNF Val66Met polymorphism has been 
associated with worse outcome in patients with unrup-
tured brain arteriovenous malformation and in patients 
with subarachnoid hemorrhage [9,10]. 
Although the previous studies included a substantial 
number of patients, these studies were performed only in 
western countries with heterogeneous ethnicities and did 
not consider the lesion location, type (ischemic or hem-
orrhagic) and volume of stroke as confounders for recov-
ery [8-10]. It is possible that different ethnic groups have 
different modifiers of gene function and a complex eth-
nic-specific pattern of gene function would be observed 
including differential effects of the polymorphism [11]. It 
has also been suggested that there is an interaction be-
tween the genetic polymorphism and environment [12]. 
Therefore, it is required to investigate the role of BDNF 
Val66Met polymorphism in the recovery after stroke in a 
different ethnic group and culture. Furthermore, because 
lesion location, type and volume of stroke have been as-
sociated with the recovery after stroke [13-16], these fac-
tors should be considered as confounders to clarify the 
effect of BDNF Val66Met polymorphism.
In this study, we investigated the effect of BDNF Val-
66Met polymorphism on the recovery after subcortical 
stroke using the modified Rankin Scale (mRS). Patients 
with copies of BDNF Val66Met polymorphism were com-
pared to their controls without a copy of BDNF Val66Met 
polymorphism after matching for initial severity, location 
and type of stroke.
MATERIALS AND METHODS
Subjects and study design
Patients admitted to the neurorehabilitation unit from 
April 2009 to June 2012 after acute (<1 month), first-ever 
subcortical stroke were recruited. Patients were excluded 
from the study if they were younger than 18 years of age, 
displayed increased intracranial pressure or did not pro-
vide written informed consent. Thirty-six patients were 
recruited. All subjects received detailed information 
about the study and provided their written consent, prior 
to determination of the presence of BDNF Val66Met poly-
morphism. mRS as a primary outcome instrument was 
assessed on admission to the neurorehabilitation unit, at 
1 month after discharge and at 3 months after discharge. 
Following measures were assessed only on admission: 
the National Institutes of Health Stroke Scale (NIHSS), 
Fugl-Meyer Assessment (FMA) Scale, Brunnstrom stage, 
Korean version of Modified Barthel Index (K-MBI), and 
Korean version of Mini-Mental Status Examination (K-
MMSE). MRIcro software (University of Nottingham 
School of Psychology, Nottingham, UK) was used to mea-
sure the stroke volume using diffusion-weighted magnet-
ic resonance imaging (MRI) in ischemic stroke patients 
and computed tomography (CT) in hemorrhagic stroke 
patients. Motor evoked potentials (MEP) were measured 
bilaterally in upper and lower limbs. MEPs were mea-
sured in all 4 extremities (in abductor pollicis brevis of 
upper limbs and in adductor hallucis of lower limbs) 
using a standard protocol [17]. Reproducible responses 
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with a minimal peak-to-peak amplitude of 200 μV in at 
least 5 of 10 consecutive trials using a figure-of-eight coil 
with a MagPro ×100 (Medtronic Inc., Farum, Denmark) 
were defined as a positive response [18]. All assessments 
of functional outcomes, stroke volume and MEP were 
performed blinded to the BDNF genotype. This research 
protocol was approved by the local Institutional Review 
Board, and this study was conducted in accordance with 
the regulatory standards of Good Clinical Practice and 
the Declaration of Helsinki (World Medical Association 
Declaration of Helsinki: Ethical Principles for Medical 
Research Involving Human Subjects, 2000).
Genotyping
Genomic DNA of the clinical samples was extracted 
using the QIAamp Blood Mini Kit (Qiagen, Valencia, 
CA, USA). Real-time polymerase chain reaction (PCR) 
reactions were performed using LightCycler 2.0 (Roche, 
Indianapolis, IN, USA). Genotyping primers and probes 
were designed using the LightCycler Probe Design Soft-
ware 2.0 (Roche). The primer sequences were NF-F 
5’-GGTTCAAGAGGCTTGACAT-3’ and NF-R 5’-TGTTT-
GCAGCATCTAGGTAAT-3’. The hybridization probe 
sequences were NF-A 5’-TTCATTGGGCCGAACTTTCT-
GGTCCTC-Fluorescein-3’ and NF-D 5’-LC Red 640- 
CCAACAGCTCTTCTATCACGTGTT-Phosphate-3’. PCR 
was performed in a total volume of 20 μL, with 2.0 μL of a 
reaction mixture comprising of LightCycler FastStart DNA 
Master Hybridization (Roche), 0.2 μM of each primer 
and probe and 2.0 μL of template DNA (50 ng/μL). The 
amplification protocol for this reaction consisted of 40, 
5-second cycles of denaturation at 94°C, 10-second of an-
nealing at 58°C and 15-second of extension at 72°C. Melt-
ing curves were acquired by measuring the fluorescence 
during a temperature transition from 40°C to 80°C at the 
rate of 0.2°C per second after 30-second of the first step. 
Fluorescence data were converted into melting peaks by 
plotting the negative derivatives of fluorescence with re-
spect to temperature (−dF/dT) as a function of tempera-
ture. The presence of the BDNF Val66Met polymorphism 
was determined according to the sequence-specific 
melting temperature: 66.5±0.5°C in the GTG/GTG homo-
zygous sample, 60.5±0.5°C in the GTG/GTG homozygous 
sample, and double peaks with two melting points in the 
GTG/ATG heterozygous sample.
Data analysis
Subject selection for analysis
All 36 participants completed the follow-up assess-
ment at 3 months post-discharge. Eight patients did not 
have the BDNF Val66Met polymorphism, 21 patients had 
one copy of the BDNF Val66Met polymorphism and seven 
patients had two copies of the BDNF Val66Met polymor-
phism. For the analysis, the patients with one or two 
Fig. 1. Diffusion weighted mag-
netic resonance imaging and com-
puted tomography scans (patient 
5 and 5’) in acute stage of stroke. 
Patient number with the apostro-
phe denotes matching of a patient 
in the Met allele (+) group to the 
patient with the same number in 
the Met allele (-) group.
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copies of the BDNF Val66Met polymorphism were pooled. 
Therefore, there were two groups for analysis: patients 
without any copy of the BDNF Val66Met polymorphism 
(Met allele (-) group) and patients with 1−2 copies of the 
BDNF Val66Met polymorphism (Met allele (+) group). The 
patients in the Met allele (-) group were matched with the 
patients in the Met allele (+) group on a one-to-one ratio 
according to stroke type (ischemic or hemorrhagic), ana-
tomical lesion involved by stroke (white matter [e.g., co-
rona radiata, internal capsule], basal ganglia, thalamus, 
pontomedullary, and cerebellum) on diffusion MRI or CT 
in the acute stage and initial stroke severity represented 
by NIHSS on admission. For matching of the NIHSS 
score, a difference in scores of up to four was allowed. 
Matching was performed by one investigator blinded to 
results of other outcomes, excluding those of NIHSS, on 
admission. As a result of matching, seven patients in each 
group were selected for analysis. The initial MRI images 
and baseline characteristics are presented in Fig. 1 and 
Table 1, respectively. One patient with large corona ra-
diata infarction in the no polymorphism group could not 
be matched due to a high NIHSS score of 18. 
Statistical analysis
Continuous variables are presented as the mean±stan-
dard deviation for normally distributed data and as the 
median with interquartile range for skewed data. Cate-
gorical variables are presented as frequency (percentage). 
To compare the baseline characteristics between the two 
groups, Student t-test or the Mann-Whitney U test (for 
non-normally distributed data) was used for continuous 
variables and chi-square test was used for categorical 
variables. An uncorrected two-tailed p<0.05 was consid-
ered statistically significant.
The mRS scores at 1 month after discharge in patients 
2 and 3 were not measured and these missing data were 
imputed by using the last observation carried forward 
approach. The effect of presence of the BDNF Val66Met 
polymorphism was evaluated with a repeated measures 
ANOVA with time (three levels: on admission, at 1 month 
and 3 months after discharge) as a within-subject factor 
and group (two levels: Met allele (+) and Met allele (-)) as 
a between-subject factor. Overall significant differences 
in time, group and interaction between time and group 
were determined by a two-tailed p<0.05. Student t-test or 
paired t-test with Bonferroni correction was applied as a 
post hoc test only when ANOVA revealed overall signifi-
cant differences. Student t-tests for mRS were performed 
at each of the three time points with the significance level 
of p<0.017 after Bonferroni correction. mRS scores at 1 
month and 3 months after discharge were compared to 
those on admission and at 1 month after discharge, re-
spectively, by the paired t-tests with the significance level 
of p<0.025 after Bonferroni correction. Statistical analysis 
was performed using the SPSS PASW ver. 18.0 (SPSS Inc., 
Chicago, IL, USA).
RESULTS
Characteristics of the patients
Table 1 shows the detailed data of the selected patients 
for analysis. The two groups were well matched for stroke 
lesion and type (Table 1, Fig. 1). Patients 5, 6, and 7 had 
higher NIHSS scores by 4 points compared to those in the 
matched patients, but the NIHSS score was not different 
between the other pairs. 
There were no significant differences between the two 
groups in terms of demographic variables, days from 
stroke onset to admission and discharge and stroke type 
(Table 2). Among functional outcomes measured on 
admission, the no BDNF Val66Met polymorphism group 
showed higher stroke volume, NIHSS, and mRS scores; 
and lower K-MBI and K-MMSE scores compared to the 
BDNF Val66Met polymorphism group; however, this dif-
ference was not statistically significant (Table 2). No sig-
nificant differences between two groups were seen in the 
FMA scale, B-stage, and MEP responses in the affected 
extremities (Table 2).
Differences in recovery ac cording to the presence of 
BDNF polymorphism measured by the mRS
A repeated measures ANOVA for mRS revealed signifi-
cant interaction between time and group (F(2, 24)=37.2, 
p<0.001) and a significant effect of time (F(2, 24)=10.8, 
p<0.001), reflecting a significant difference between the 
Met allele (+) group and the Met allele (-) group (Fig. 2). 
Post-hoc analysis with Student t-test at each time point 
with Bonferroni correction revealed a significant differ-
ence in mRS scores at 3 months post-discharge between 
the two groups (p=0.01), although no difference in mRS 
scores was evident at 1 month post-discharge between 
the two groups (Fig. 2). There were significant improve-
ments between mRS scores on admission and mRS 
scores at 1 month post-discharge (p=0.02), and between 
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mRS scores at 1 month post-discharge and mRS scores at 
3 months post-discharge (p=0.004) in the Met allele (-) 
group (Fig. 2). In the Met allele (+) group, there were no 
significant improvements in mRS scores although a trend 
for improvement was evident (Fig. 2).
DISCUSSION
In this study, we demonstrated that the presence of 
BDNF Val66Met polymorphism may be associated with 
worse functional recovery after subcortical stroke in Ko-
rean patients. This finding is consistent with the results 
of previous studies performed in western countries with 
heterogeneous ethnicities [8-10], thereby suggesting that 
the BDNF Val66Met polymorphism is a poor prognostic 
factor for recovery after stroke that can be extrapolated to 
other ethnic or culture groups despite the possible differ-
ential effects of the genetic polymorphism [11,12]. 
We only included patients with stroke involving the 
subcortical brain structure in this study. Although some 
researchers have suggested the possibility that the re-
covery mechanism of subcortical stroke may be different 
from that of cortical stroke [19-21], evidence suggests that 
changes in cortical plasticity are also important for the 
recovery even after subcortical stroke [22]. Plastic chang-
es around the cortical lesion, which has a functional con-
nectivity with the damaged subcortical area, are associat-
ed with recovery after subcortical stroke [23]. Therefore, 
it seems that BDNF has an effect on the plastic changes in 
the cortex that are associated with the damaged subcorti-
cal area, and a lack of secretion of BDNF in a patient with 
BDNF Val66Met polymorphism is associated with worse 
recovery. 
Table 2. Baseline characteristics of patients according to 









Age (yr) 65.0±7.8 69.0±13.8 0.518b)
Gender 
   Male 4 (57.1) 3 (42.9) 0.593c)
   Female 3 (42.9) 4 (57.1)
Onset to admission (day) 10.9±4.8 13.3±4.8 0.362b)
Onset to discharge (day) 26.9±5.9 28.1±7.7 0.731b)
Stroke type
   Ischemic 6 (85.7) 6 (85.7) 1.000c)
   Hemorrhagic 1 (14.3) 1 (14.3)
Stroke volume (mL)a) 1.8 (6.3) 0.8 (8.3) 0.259d)
NIHSSa) 5 (6) 3 (3) 0.383d)
mRSa) 4 (1) 3 (1) 0.383d)
FMA in the affected side 6 6
   U/E 5.2±0.8 5.0±0.9 0.734b)
   L/E 23.7±13.3 23.7±11.0 1.000b)
K-MBI 50.0±18.8 52.6±20.5 0.811b)
B-stage
   Arma) 5 (1) 5 (0) 0.456d)
   Handa) 5 (1) 5 (1) 1.000d)
   Lega) 5 (1) 5 (1) 0.805d)
K-MMSE 19.7±6.4 21.9±6.1 0.533b)
MEP (-)e) in the affected 
side
7 6
   U/E 4 3 0.797c)
   L/E 2 2 0.853c)
Values are presented as mean±standard deviation or 
number (%).
NIHSS, National Institutes of Health Stroke Scale; mRS, 
modified Rankin Scale; FMA, Fugl-Meyer Assessment; U/
E, upper extremity; L/E, lower extremity; K-MBI, Korean 
version of Modified Barthel Index; B-stage, Brunnstrom 
stage; K-MMSE, Korean version of Mini-Mental Status 
Examination; MEP, motor evoked potential.
a)Median (interquartile range), b)Student’s t-test for in-
dependent samples, c)chi-square test, d)Mann-Whitney U 
test, e)no response in MEP.
Fig. 2. Modified Rankin Scale (mRS) on admission to 
the rehabilitation unit, at 1 month post-discharge and 
3 months post-discharge according to the presence of 
the Met allele. *p<0.017 with Bonferroni correction by 
student’s t-test, †p<0.025 with Bonferroni correction by 
paired t-test.
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Significant differences between the two groups in the 
recovery measured by mRS were observed at 3 months 
after discharge from the neurorehabilitation unit, which 
corresponds to approximately 4 months after stroke on-
set; and it has been suggested that maximal motor recov-
ery is achieved by plastic changes in the brain during this 
period [24]. BDNF increases the plastic changes in the 
brain, which are associated with the recovery of motor, 
cognitive and speech functions after stroke. Therefore, 
the differences in BDNF levels that are caused due to the 
presence of BDNF Val66Met polymorphism can cause 
differences in the recovery induced by plastic changes 
in the brain during this period. The reason why there 
was no significant difference in the function at 1 month 
post-discharge between groups is unclear. It is possible 
that the mRS represents a very broad range of function, 
such that differences in the functional status measured 
by mRS at that time point could not be detected due to 
its low sensitivity [25] given the small sample size of our 
study. Another possible reason is that the initial stroke 
severity measured by NIHSS was higher in the Met al-
lele (-) group. Patients 4, 5, 6, and 7 in the Met allele (-) 
group showed a higher stroke severity compared to their 
controls in the Met allele (+) group (Table 1). Because the 
initial severity of stroke is related with poor functional 
recovery, the Met allele (-) group with higher severity of 
stroke was expected to have a worse mRS score; however, 
this group showed better functional outcome at 3 months 
post-discharge. Therefore, it is possible that because of 
the higher initial stroke severity, approximately 2 months 
or more were needed for the patients without the Met 
allele to keep up with the gap of initial stroke severity be-
tween the two groups. 
This study had several limitations that need to be con-
sidered. First, although the two groups were perfectly 
matched for location and type of stroke, stroke severity 
measured by NIHSS was not the same between patients 
4, 5, 6 and 7 of the Met allele (-) group and their matched 
cases in the Met allele (+) group, and these patients 
showed a higher stroke severity compared to their con-
trols in the Met allele (+) group. Because the initial se-
verity of stroke is related with poor functional recovery 
[26,27], the higher severity of stroke in the Met allele (-) 
group could be associated with worse mRS; however, a 
better functional outcome was achieved in the Met allele 
(-) group. Secondly, three patients (patients 1’, 4’, and 6’) 
in the Met allele (+) group were substantially older than 
their matched cases in the Met allele (-) group. Because 
older age has been considered as a poor prognostic fac-
tor for functional recovery after stroke [28], age differ-
ences between the groups can lead to the differences in 
functional recovery. However, there were no statistically 
significant differences in age between the Met allele (-) 
group and the Met allele (+) group (Table 2). Further-
more, the above three patients had better values for 
some prognostic variables of recovery compared to their 
matched cases. Patient 1’ had a lower stroke volume and 
a better K-MBI score, and patients 4’ and 6’ had a less 
severe stroke according to the NIHSS compared to their 
matched cases. Therefore, we think that the differences in 
functional recovery according to the presence of Met al-
lele in this study cannot be explained by the substantially 
older age of three patients in the Met allele (+) group 
than their matched controls. Thirdly, the sample size was 
small compared to that in previous studies [8-10]. How-
ever, there was a statistically significant improvement in 
the mRS score only in the Met allele (-) group, and the 
mRS score at 3 months post-discharge in the Met allele (-) 
group was also significantly better than the mRS score at 
3 months post-discharge in the Met allele (+) group (Fig. 
2). This means that the improvement in function was 
consistent only in the Met allele (-) group, which showed 
statistically significant changes in the mRS scores despite 
the small sample size. Fourthly, we only included the 
mRS as a functional outcome. Although BDNF may also 
affect the recovery of various impairments after stroke 
[2,29,30], it was difficult to investigate the possible differ-
ential effect of BDNF Val66Met polymorphism with mRS 
in this study because mRS is a global functional outcome 
measure [25,31,32]. Fifthly, the one and two copies of 
BDNF Val66Met polymorphisms were combined into one 
group for analysis. Although it has been suggested that 
there is a possible dose-response relationship according 
to the number of Met alleles, we could not investigate this 
phenomenon in this study due to the small sample size. 
Finally, the rehabilitation therapy and patient’s medica-
tions after discharge were not controlled, which could 
influence the recovery after stroke. 
However, this study has several strengths since many 
possible confounders for recovery after stroke such as 
location, type, stroke severity, stroke volume, and motor 
function measured by FMA and B-stage, cognitive func-
tion measured by K-MMSE and corticospinal tract integ-
rity assessed by MEP were initially balanced between the 
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two groups using a matched control and variable func-
tional measurement.
In conclusion, BDNF val66met polymorphism may be 
associated with worse functional outcome in Korean pa-
tients with subcortical stroke. Therefore, BDNF Val66Met 
polymorphism should be considered as an important 
prognostic factor for recovery and responses to rehabili-
tation therapies after stroke in Korean patients. Further-
more, there is a need for developing different rehabilita-
tion strategies for the population with the BDNF Val66Met 
polymorphism. Finally, further studies assessing differ-
ent outcomes for various functional domains of stroke 
recovery are needed to clarify the role of BDNF Val66Met 
polymorphism.
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